Rationale and Design of the PASSIVATE‐CAP Trial: The Preventive Intervention Value of Drug‐Coated Balloons in Vulnerable Coronary Atherosclerotic Plaques

Patients with acute coronary syndrome (ACS) face a significantly increased risk of cardiovascular events due to vulnerable plaques. However, no clear evidence supports performing preventive percutaneous coronary intervention (PCI) for non‐flow‐limiting vulnerable plaques. To address this gap, the PASSIVATE‐CAP study was designed to investigate the therapeutic potential of drug‐coated balloon (DCB) for treating non‐flow‐limiting vulnerable plaques.